Skip to the content
  • Our Company
    • Management Team
    • Board Members
    • Events
  • Our Approach
  • Partner
  • Careers
  • Resources
  • News
Menu
  • Our Company
    • Management Team
    • Board Members
    • Events
  • Our Approach
  • Partner
  • Careers
  • Resources
  • News
  • Contact
Menu
  • Contact

High-throughput sequencing enhanced phage display enables the identification of patient-specific epitope motifs in serum.

read more
Path 3
  • Scientific Publication
  • August 6, 2015

Christiansen A, et al. (2015) “High-throughput sequencing enhanced phage display enables the identification of patient-specific epitope motifs in serum.” Scientific Reports. 5: 12913. doi: 10.1038/srep12913

Abstract

Phage display is a prominent screening technique with a multitude of applications including therapeutic antibody development and mapping of antigen epitopes. In this study, phages were selected based on their interaction with patient serum and exhaustively characterised by high-throughput sequencing. A bioinformatics approach was developed in order to identify peptide motifs of interest based on clustering and contrasting to control samples. Comparison of patient and control samples confirmed a major issue in phage display, namely the selection of unspecific peptides. The potential of the bioinformatic approach was demonstrated by identifying epitopes of a prominent peanut allergen, Ara h 1, in sera from patients with severe peanut allergy. The identified epitopes were confirmed by high-density peptide micro-arrays. The present study demonstrates that high-throughput sequencing can empower phage display by (i) enabling the analysis of complex biological samples, (ii) circumventing the traditional laborious picking and functional testing of individual phage clones and (iii) reducing the number of selection rounds.

PreviousLoss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
NextAutoantibody targets in vaccine-associated narcolepsy.
PreviousLoss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
NextAutoantibody targets in vaccine-associated narcolepsy.
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact

603 Science Dr
Madison, WI, USA 53711

LinkedIn
  • Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech
    Read More